Join to View Full Profile
619 19th Street SouthBirmingham, AL 35233
Phone+1 205-934-6600
Are you Dr. Shaw?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. George Shaw, MD is an oncologist in Birmingham, Alabama. He is currently licensed to practice medicine in Alabama, Pennsylvania, and Michigan.
Education & Training
University of MichiganResidency, Internal Medicine, 1980 - 1983
Ohio State University College of MedicineClass of 1980
Certifications & Licensure
PA State Medical License 2013 - 2026
AL State Medical License 1985 - 2022
MI State Medical License 1981 - 1985
American Board of Internal Medicine Internal Medicine
Publications & Presentations
PubMed
- 12 citationsDynamics and origin of rebound viremia in SHIV-infected infant macaques following interruption of long-term ART.Veronica Obregon-Perko, Katherine M. Bricker, Gloria Mensah, Ferzan Uddin, Laura Rotolo
JCI Insight. 2021-10-26 - 18 citationsAntibody responses induced by SHIV infection are more focused than those induced by soluble native HIV-1 envelope trimers in non-human primatesJelle van Schooten, Marlies M. van Haaren, Hui Li, Laura E. McCoy, Colin Havenar-Daughton
Plos Pathogens. 2021-08-25 - 6 citationsEnhanced Ability of Plant-Derived PGT121 Glycovariants To Eliminate HIV-1-Infected Cells.Sai Priya Anand, Shilei Ding, William D. Tolbert, Jérémie Prévost, Jonathan Richard
Journal of Virology. 2021-07-07
Grant Support
- SHIV-guided design of novel HIV-1 fusion peptide immunogensUNIVERSITY OF PENNSYLVANIA2024–2028
- SHIV Env-antibody coevolution as a molecular guide to HIV-1 V3 glycan targeted vaccine designUNIVERSITY OF PENNSYLVANIA2017–2027
- B cell lineage directed rational vaccine strategies based on CAP256SU Env-Ab coevolutionUNIVERSITY OF PENNSYLVANIA2022–2026
- HIV-1 Q23.17 Env: Engineering a novel immunogen to elicit broadly neutralizing antibodiesUNIVERSITY OF PENNSYLVANIA2021–2026
- Combining germline-targeting, B cell immunofocusing and Env-Ab coevolution strategies to induce HIV Envelope V2-apex broadly neutralizing antibodiesUNIVERSITY OF PENNSYLVANIA2021–2026
- Combining germline-targeting, B cell immunofocusing and Env-Ab coevolution strategies to induce HIV Envelope V2-apex broadly neutralizing antibodiesUNIVERSITY OF PENNSYLVANIA2021–2026
- HIV-1 Q23.17 Env: Engineering a novel immunogen to elicit broadly neutralizing antibodiesUNIVERSITY OF PENNSYLVANIA2021–2026
- Combining germline-targeting, B cell immunofocusing and Env-Ab coevolution strategies to induce HIV Envelope V2-apex broadly neutralizing antibodiesUNIVERSITY OF PENNSYLVANIA2021–2026
- HIV-1 Q23.17 Env: Engineering a novel immunogen to elicit broadly neutralizing antibodiesUNIVERSITY OF PENNSYLVANIA2021–2026
- Combining germline-targeting, B cell immunofocusing and Env-Ab coevolution strategies to induce HIV Envelope V2-apex broadly neutralizing antibodiesUNIVERSITY OF PENNSYLVANIA2021–2026
- Combining germline-targeting, B cell immunofocusing and Env-Ab coevolution strategies to induce HIV Envelope V2-apex broadly neutralizing antibodiesUNIVERSITY OF PENNSYLVANIA2021–2026
- Combining germline-targeting, B cell immunofocusing and Env-Ab coevolution strategies to induce HIV Envelope V2-apex broadly neutralizing antibodiesUNIVERSITY OF PENNSYLVANIA2021–2026
- HIV-1 Q23.17 Env: Engineering a novel immunogen to elicit broadly neutralizing antibodiesUNIVERSITY OF PENNSYLVANIA2021–2026
- HIV-1 Q23.17 Env: Engineering a novel immunogen to elicit broadly neutralizing antibodiesUNIVERSITY OF PENNSYLVANIA2021–2026
- HIV-1 Q23.17 Env: Engineering a novel immunogen to elicit broadly neutralizing antibodiesUNIVERSITY OF PENNSYLVANIA2021–2026
- HIV-1 Q23.17 Env: Engineering a novel immunogen to elicit broadly neutralizing antibodiesUNIVERSITY OF PENNSYLVANIA2021–2026
- Combining germline-targeting, B cell immunofocusing and Env-Ab coevolution strategies to induce HIV Envelope V2-apex broadly neutralizing antibodiesUNIVERSITY OF PENNSYLVANIA2021–2026
- Reverse Vaccinology in SHIV Infected Macaques as a Molecular Guide for HIV-1 Vaccine DesignUNIVERSITY OF PENNSYLVANIA2021–2025
